Core Viewpoint - The company, Kewei Medical, plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [1][2]. Group 1: H-Share Issuance and Listing - Kewei Medical's board and supervisory board approved the proposal for issuing H-shares and listing on the Hong Kong Stock Exchange [1]. - The company aims to accelerate its global strategy and improve its overseas business capabilities through this issuance [1]. - The timing and specifics of the issuance will be determined based on market conditions and shareholder approval within a 24-month period [1]. Group 2: Regulatory Approval and Uncertainty - The issuance and listing are subject to approval from various regulatory bodies, including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [2]. - There is significant uncertainty regarding whether the issuance will receive the necessary approvals and ultimately be implemented [2]. Group 3: Previous IPO and Financials - Kewei Medical raised a total of 3.724 billion yuan from its initial public offering (IPO) in October 2021, with a net amount of 3.527 billion yuan after expenses [3]. - The company initially planned to raise 1.007 billion yuan for various projects, including a health monitoring production base and a smart medical industrial park [3]. - The total issuance costs for the IPO were 197 million yuan, with underwriting fees amounting to 174 million yuan [4].